Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Magalhaes, Maria Eliane C ^a   Cavalcanti, Breno A ^b   Cavalcanti, Saulo ^b   Giannella Neto, Daniel ^c  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b University of Medical Sciences of Minas Gerais   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; THIAZIDE DIURETIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTERIAL WALL THICKNESS; BODY MASS; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; ENDOCRINOLOGY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION;

EID: 77953425018     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-2     Document Type: Note

References (40)

1. From the triumvirate to the ominous octet: a new paradigma for the treatment of type 2 diabetes. RA DeFronzo, Diabetes 2009 58 773 795 10.2337/db09-9028 19336687
2. B cell deficit and increase beta cell apoptosis in humans with type 2 diabetes. AE Buttler J Janson S Bonner-Weir R Ritzel RA Rizza PC Butler, Diabetes 2003 52 102 110 10.2337/diabetes.52.1.102 12502499
3. Diabetes and endothelial dysfunction: a clinical perspective. JC Escandon M Cipolla, Endocrine Reviews 2001 22 36 52 10.1210/er.22.1.36 11159815
4. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group, Diabetes 1979 28 1039 1057 510803
5. Clinical practice recommendations Diagnosis and classification of diabetes mellitus. American Diabetes Association, Diabetes Care 2008 28 suppl 1 55 S60
6. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. S Wild A Roglic R Sicree H King, Diabetes Care 2004 27 1047 53 10.2337/diacare.27.5.1047 15111519
7. Identification of individuals with insulin resistance using routine measurements. SE Stern K Williams E Ferranini RA DeFronzo C Bogardus MP Stern, Diabetes 2005 54 333 9 10.2337/diabetes.54.2.333 15677489
8. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group, N Engl J Med 2002 346 393 403 10.1056/NEJMoa012512 11832527
9. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998 352 837 853 10.1016/S0140-6736(98)07019-6 9742976
10. the Current Definition for Diabetes Relevant to Mortality Risk From All Causes and Cardiovascular and Noncardiovascular Diseases? The DECODE Study Group, Diabetes Care 2003 26 688 699 10.2337/diacare.26.3.688 12610023
11. Em Classificaço Etiolágica do Diabetes Mellitus. Tratamento e acompanhamento do Diabetes Mellitus, Diretrizes da Sociedade Brasileira de Diabetes 2007 11 13
12. V Diretrizes Brasileiras de Hipertenso Arterial. Sociedade Brasileira de Cardiologia, Arq Bras Cadiol 2007 89 1 79
13. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). G Mancia G De Backer A Dominiczak, et al. J Hypertens 2007 25 1105 87 10.1097/HJH. 0b013e3281fc975a 17563527
14. Contribution of B-cell Dysfunction and insulin resistance to the Pathogenesis of Impaire Glucose Tolerance and impaired fasting glucose. MA Abdul-Ghani D Tripathy RA DeFronzo, Diabetes Care 2006 29 1130 1139 10.2337/dc05-2179 16644654
15. Coronary Artery Calcification in Type 2 Diabetes and Insulin Resistance. JB Meigs MG Larson R B D'Agostino D Levy ME Clouse DM Nathan PWF Wilson CJ O'Donnell, Diabetes Care 2002 25 1313 1319 10.2337/diacare.25.8.1313 12145227
16. Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes. KJ Hunt K Williams D Rivera DH O'Leary SM Haffner MP Stern C Gonzales Villalpando, Arterioscler Thromb Vasc Biol 2003 23 1845 1850 10.1161/01.ATV.0000093471.58663.ED 12958039
17. Euro Heart Survey. M Lentzen, Eur Heart J 2006 24 2969 74 10.1093/eurheartj/ehl363
18. Intimal media thickness, glucose intolerance and metabolic syndrome in Asian Indians - the Chennai Urban Rural Epidemiology Study (CURES-22). V Mohan K Gokulakrishnan S Sandeep BK Srivastava R Ravikumar R Deepa, Diabet Med 2006 23 845 50 10.1111/j.1464-5491.2006.01898.x 16911621
19. Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. B Isomaa P Almgren Y Tuomi F Björn K Lahti M Nissén M-R Taskinen L Groop, Diabetes Care 2001 24 683 689 10.2337/diacare.24.4.683 11315831
20. The epidemiology of impaired glucose tolerance and hypertension. WB Kannel PW Wilson TJ Zhang, Am Heart J April 1991 21 1268 73 10.1016/0002- 8703(91)90432-H
21. Glucose Tolerance in Patients with Myocardial Infarction. A Norhammar M Bartnik, Lancet 2002 359 2140 4 10.1016/S0140-6736(02)09089-X 12090978
22. China Heart Survey. DY Hu, Eur Heart J 2006 27 2573 9 10.1093/eurheartj/ehl207 16984927
23. Association of high sensitivity C-reactive protein (hsCRP) and tumour necrosis factor-alpha (TNF-alpha) with carotid intimal medial thickness in subjects with different grades of glucose intolerance - the Chennai Urban Rural Epidemiology Study (CURES-31). K Gokulakrishnan R Deepa V Mohan, Clin Biochem 2008 41 480 5 18328265
24. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. M Tominaga H Eguchi H Manaka K Igarashi T Kato Sekikawa, Diabetes Care 1999 22 920 924 10.2337/diacare.22.6.920 10372242
25. Subclinical States of Glucose Intolerance and Risk of Death in the U.S. SH Saydah CM Loria MS Eberhardt FL Brancati, Diabetes Care 2001 24 447 453 10.2337/diacare.24.3.447 11289466
26. Report of the expert committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association, Diabetes Care 1998 Suppl 1 5
27. The Prevention of Diabetes Mellitus. E Joslin, JAMA 1921 76 79 84
28. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects - a population-based study comparing three different definitions. PM Nilsson G Engstrom B Hedblad, Diabetic Medicine 2007 24 464 72 10.1111/j.1464-5491.2007.02142.x 17381496
29. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. XR Pan GW Li YH Hu WY Wang ZX An ZX Hu J Lin JZ Xiao HB Cao PA Liu XG Jiang YY Jiang JP Wang H Zheng PH Bennett BV Howard, Diabetes Care 1997 20 537 544 10.2337/diacare.20.4.537 9096977
30. The Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impared glucose tolerance. J Tuomiehto J Lindström A Louheranta TT Valle H Hamalainen M Rastas P Ilanne-Parikka V Saminen J Eriksson S Keinanen-Kiukaanniemi M Laakso M Uusitupa, N Engl J Med 2001 344 1343 1350 10.1056/NEJM200105033441801 11333990
31. Randomized Controlled Trial of a New Dietary Education Program to Prevent Type 2 Diabetes in a Hight-Risk Group of Japonese Male Workers. M Watanabe K Yamaoka M Yokotsuka T Tango, Diabetes Care 2003 26 3209 3214 10.2337/diacare.26.12.3209 14633803
32. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inihibiton to prevent type 2 diabetes in a population with impaired glucose tolerance. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. JL Chiasson R Gomis M Hanefeld RG Josse A Karasik M Laakso, Diabetes Care 1998 21 1720 1725 10.2337/diacare.21.10.1720 9773737
33. and Prevention of Type 2 Diabetes with Troglitazone in the Diabetes Prevention Program: TRIPOD. WC Knowler RF Hamman SL Edelstein E Barrett-Connor DA Ehrmann EA Walker SE Fowler DM Nathan SE Kahn, Diabetes 2005 54 1150 1156 10.2337/diabetes.54.4.1150 15793255
34. Effect of Rosiglitazone on the frequency of diabetes in patients wiyh impaired glucose tolerance or impaired fasting glucose: randomised controlled trial. DREAM Trial Investigatores, Lancet 2006 368 1096 1105 10.1016/S0140-6736(06)69420-8 16997664
35. Medical management of hyperdysglicaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. DM Nathan, et al. Diabetes Care 2008 31 1 11 10.2337/dc08-0545
36. Continuous relationships between non-diabetic hyperdysglicaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. ELM Barr EJ Boyko PZ Zimmet R Wolfe AM Tonkin JE Shaw, Diabetologia 2009 52 415 424 10.1007/s00125-008-1246-y 19130039
37. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. GA Nichols TA Hillier JB Brown, The American Journal of Medicine 2008 121 519 524 10.1016/j.amjmed.2008.02.026 18501234
38. The Brazilian Cooperative Group on the study of Diabetes Prevalence. Multicenter study of the prevalence of diabetes mellitus and Impaired Glucose Tolerance in the urban Brasilian population aged 30-69 years. D Malerbi LJ Franco, Diabetes Care 1992 15 1509 1516 10.2337/diacare.15.11.1509 1468278
39. Prevalence of diabetes mellitus and impaired glucose tolerance in the urban population aged 30-69 years in Ribeiro Preto. MT Torquato RM Montenegro Jnr LA Viana RA de Souza CM Lanna JC Lucas C Bidurin MC Foss, Med J 2003 121 6 224 230
40. Estimating the cardiovascular risk in patients with diabetes type 2: A National Multicenter Study in Brazil. MB Gomes D Giannella M Faria M Tambascia RM Fonseca R Réa G Macedo J Modesto Filho H Schmid AV Bittencourt S Cavalcanti N Rassi H Pedrosa SA Dib, Diabetol Metab Syndr 2009 1 1 22 10.1186/1758-5996-1-22 19860912